A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Phase of Trial: Phase IV
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Portal hypertension; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms PORTICO
- Sponsors Actelion Pharmaceuticals
- 17 Jul 2017 Planned End Date changed from 1 Oct 2017 to 15 Mar 2018.
- 17 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 15 Feb 2018.
- 14 Sep 2015 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017, as reported by ClinicalTrials.gov.